OTraces lands $2M Florida grant to validate blood test for prostate cancer
What's the deal? OTracesDealroom has a profile for this one. Try Dealroom →, a proteomics diagnostics firm, has received a $2 million grant from the Florida Department of HealthDealroom has a profile for this one. Try Dealroom → to fund clinical validation of its blood-based prostate cancer test. The award comes from the state's Florida Cancer Innovation Fund and moves the company closer to commercialisation.
What's the endgame? The grant will support a 12-month, prospective multi-center study of roughly 954 men with elevated PSA levels. The goal is to validate the proteomic blood test for biopsy decision support — helping doctors decide which patients actually need an invasive biopsy.
Why now? The Florida Cancer Innovation Fund backs peer-reviewed cancer projects with near-term clinical impact. Its choice signals state-level interest in non-invasive diagnostics and potential future reimbursement pathways if the data prove strong.
What could go wrong? Proteomics-based prostate tests remain an emerging area with many candidates and few widely adopted tools. Recent reviews stress the need for robust validation and cost-effectiveness data — exactly what this grant is meant to produce, but the outcome is not guaranteed.
OTraces is not alone in chasing biopsy-reducing technology. Weill CornellDealroom has a profile for this one. Try Dealroom → is running an NCIDealroom has a profile for this one. Try Dealroom →-funded, roughly $4 million PSMA-PET imaging trial for active surveillance, showing how imaging and proteomics compete to refine prostate cancer monitoring.
The signal: This is a regional, early-commercialisation milestone rather than a major financing event. It shows public funders will underwrite sizable clinical validation for novel proteomic tests, but the modest scope means it changes little without successful trial results.
Read more: 360Dx
Image credit: Neeta Lind
